The results of the ImpACT-24M usability study were published today by Stroke titled: "Refined Sphenopalatine Ganglion Stimulator Placement and Intensity Setting to Augment Blood Flow and Neurologic... Read more about ImpACT-24M study results published by Stroke
The results of the ImpACT-24B clinical trial were published today by The Lancet in an article titled: "An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic... Read more about ImpACT-24B results published by The Lancet
The Data Safety Monitoring Board (the "DSMB") for BrainsGate's study examined the interim results and deterimined the results support the continuation of the stud Read more about ImpACT24 Interim Results
Established in 2000, BrainsGate is a medical device company committed to developing innovative therapies for patients suffering from Central Nervous System (CNS) diseases.
BrainsGate's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow.
